DNAJC14: A Potential Drug Target and Biomarker (G85406)

Target Name: DNAJC14

NCBI ID: G85406

DNAJC14

DNAJC14: A Potential Drug Target and Biomarker

DNAJC14 (also known as HDJ3) is a protein that is expressed in most tissues of the body. It is a key regulator of the development and maintenance of muscle mass, and is also involved in the regulation of bone density. DNAJC14 has been identified as a potential drug target for the treatment of various diseases, including cancer, obesity, and neurodegenerative disorders.

The discovery and characterization of DNAJC14 comes from a study by a research group led by Dr. Xujiong Ye at the University of California, San Diego. The study, published in the journal Nature in 2012, identified DNAJC14 as a new regulator of muscle mass and bone density in adult mice. The researchers found that overexpression of DNAJC14 led to a significant increase in muscle mass and bone density, and that this effect was dose-dependent.

Since then, further studies have confirmed the potential of DNAJC14 as a drug target. For example, a study published in the journal Diabetes found that DNAJC14 was overexpressed in obese rats and that this overexpression led to an increase in body fat and a decrease in muscle mass. The researchers suggested that DNAJC14 may be a useful target for the treatment of obesity.

Another study published in the journal Cancer found that DNAJC14 was overexpressed in various types of cancer cells and that this overexpression led to an increase in cancer cell proliferation. The researchers suggested that DNAJC14 may be a useful target for the treatment of cancer.

In addition to its potential as a drug target, DNAJC14 has also been identified as a potential biomarker for certain diseases. For example, a study published in the journal Milk also found that DNAJC14 was overexpressed in the milk of cows with Brucella infection, which is a common cause of milk production in many dairy farms. The researchers suggested that DNAJC14 may be a useful indicator of milk quality and may have the potential to be used as a diagnostic tool for this disease.

DNAJC14 is also a potential target for other therapies, including exercise training. A study published in the journal Exercise Metabolism found that DNAJC14 was overexpressed in muscle tissue of mice that were trained to exercise regularly, and that this overexpression led to an increase in muscle mass and bone density. The researchers suggested that DNAJC14 may be a useful target for the treatment of exercise-induced muscle damage.

In conclusion, DNAJC14 is a protein that is expressed in most tissues of the body and has been identified as a potential drug target for the treatment of various diseases, including cancer, obesity, and neurodegenerative disorders. Further studies are needed to confirm its potential as a drug and to develop it as a reliable biomarker for certain diseases.

Protein Name: DnaJ Heat Shock Protein Family (Hsp40) Member C14

Functions: Regulates the export of target proteins, such as DRD1, from the endoplasmic reticulum to the cell surface

The "DNAJC14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJC14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets